# Applying Treatment Advances in Castration-Resistant Prostate Cancer: The influence of serial digital education on the uro-oncology team












Authors: Tariqa Ackbarali, PhD(c)¹; Elizabeth del Nido, BA¹; Neal D. Shore, MD² 1 - PlatformQ Health; 2 - Carolina Urologic Research Center

### INTRODUCTION


Improvements in the understanding of prostate tumor development have spurred advances in biomarker testing and new therapies for prostate cancer, providing clinicians with expanded testing and treatment options. However, these changes have led to competence gaps regarding the use of biomarker testing, integration of PARP inhibitors, application of new data for nmCRPC and mCRPC, and adverse event management. To address these needs, a serial educational initiative was designed for the urology-oncology team.





# **Educational Program and Evaluation Details**

METHODS



A 4-part CE activity was launched live-online in December, 2020, and remains on-demand through December, 2021 at UroCareLive.com and OMedLive.com. The activity was launched in partnership with Large Urology Group Practice Association (LUGPA) and included case presentations, live polling, and live audience Q&A.

Knowledge/competence questions were administered pre-, post-, and at 2 months post-activity. Responses from learner polling, and 2 mos. follow-up surveys were analyzed for engagement, lessons learned, and continuing gaps. McNemar tests compared matched pair responses (pre/post & pre/2mos) with Cohen's d for effect size.

# METHODS (CONT.)

## **Overall Initiative Title:**

2nd Annual Virtual Summit: Optimizing Uro-Oncology Care for Patients with Metastatic and Nonmetastatic Prostate Cancer

Session 1: Utilizing Biomarkers to Navigate Treatment Decisions for Prostate Cancer Patients

Session 2: Integrating New Therapies in the Management of Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC) Session 3: Optimizing Treatment for Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Session 4: PARP Inhibition: A New Paradigm in Prostate Cancer Care

Neal D. Shore, MD, Carolina Urologic Research Center Simpa S. Salami, MD, PhD, University of Michigan A. Oliver Sartor, MD, Tulane University School of Medicine Tomasz (Tom) M. Beer, MD, FACP, Oregon Health & Science University David I. Quinn, MD, Keck School of Medicine of USC

- CME activities were produced and broadcast live-online on www.UroCareLive.com and www.OMedLive.com, and then made available on-demand for 12 months The activities featured:
- Learners encouraged to submit questions before and during the live program

### **Accredited Provider**

Global Education Group


# **Collaborative Partner**

Large Urology Group Practice Association

# RESULTS (CONT.)



genetic testing of family members



n=231 pre; 113 post; 45, 2 mos. follow-up n=282 pre; 142 post; 51, 2 mos. follow-up

2 mos.

# Statistically significant improvements; p<.05, matched learners, comparison of pre to post and pre to 2

**Post** 

2 mos.

# Changes in Knowledge/Competence Practice Barriers and Challenges

# Top 2 Barriers to Adopting New Agents:

32% Lack of provider awareness of availability of new agents

22% Lack of provider experience with new agents

### Top 2 Barriers to Implementing Changes in Practice:

42% Lack of knowledge of evidence-based strategies

19% Lack of tim e/resources to consider changes in current practice



30% Affordability of testing

23% Lack of guideline clarity

18% Institutional and payer requirements

13% Patient understanding of treatment options

### **Biomarker Testing Preference**





Tissue-based






Urine-based

do not perform biomarker tests for my patients

# RESULTS AS OF 8/9/2021

# **Learners and Engagement** A 1,016 total learners (CE) CE credits awarded total slide downloads

# Positive Impact on Clinical Practice



### learners reported the activity positively impacted clinical practice

recommend germ line testing with any recurrence

participation in th

treatment

patient experience/outcomes

learners reported the activity positively impacted

counseling and

communication

with patients

I analyze the patient's history and symptoms in to stratify them for a better therapy option

Tested a patient and

they were found to be

BRCA2+ and is now

on a clinical trial with

a PARPi

Post

Better knowledge of androgen receptor inhibitors

Better results are

obtained from

therapeutic

modalities when

started referring

in patients with gBRCA mCRPC

Patients are more

informed regarding

their disease

# CONCLUSIONS

# **Educational Next Steps for the Management of Prostate Cancer**

- Differentiating bone-modifying agents in nmCRPC
- Monitoring PSA levels in low-risk vs high-risk disease
- Recognizing and addressing treatment adverse events
- Treatment algorithms for mCRPC including how to sequence therapy
- Management of biochemical recurrence
- Differentiating second-generation antiandrogen therapies
- Strategies to maintain or enhance QOL

This activity is supported by educational grants from Advanced Accelerator Applications USA, Inc.,

Author contact: tackbarali@platformq.com Astellas, Clovis Oncology, Inc., Dendreon, Exact Sciences, Myriad Genetics, and Sanofi Genzyme.